The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure
Abstract
Background —The RALES study showed that spironolactone, added to conventional therapy for chronic heart failure, dramatically reduced mortality. We tested the hypothesis that this benefit was partially due to improvement in endothelial function and/or to amplified suppression of the vascular renin-angiotensin axis. Methods and Results —We performed a randomized, placebo-controlled, double-blind crossover study on 10 patients with NYHA class II to III chronic heart failure on standard diuretic/ACE inhibitor therapy, comparing 50 mg/d spironolactone (1 month) versus placebo. Forearm vasculature endothelial function was assessed by bilateral forearm venous occlusion plethysmography using acetylcholine and N -monomethyl- l -arginine (L-NMMA), with sodium nitroprusside as a control vasodilator. Also, vascular ACE activity was assessed by use of angiotensin (Ang) I, with Ang II as a control vasoconstrictor. Spironolactone significantly increased the forearm blood flow response to acetylcholine (percentage change in forearm blood flow [mean±SEM], 177±29% versus 95±20%, spironolactone versus placebo; P <0.001), with an associated increase in vasoconstriction due to L-NMMA (−35±6% versus −18±4%; P <0.05). The Ang I response was also significantly reduced with spironolactone ( P <0.05), with Ang II responses unaltered. Conclusions —Spironolactone improves endothelial dysfunction, increases NO bioactivity, and inhibits vascular Ang I/Ang II conversion in patients with heart failure, providing novel mechanisms for its beneficial effect on cardiovascular mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
K+ is an endothelium-derived hyperpolarizing factor in rat arteries
Edwards, G., Dora, K. A., Gardener, M. J., Garland, C. J., & Weston, A. H. (1998) · Nature · doi:10.1038/24388 · Cited by 1,058
Measuring Forearm Blood Flow and Interpreting the Responses to Drugs and Mediators
Benjamin, N., Calver, A., Collier, J., Robinson, B., Vallance, P., & Webb, D. (1995) · Hypertension · doi:10.1161/01.hyp.25.5.918 · Cited by 399
Duprez, D. (1998) · European Heart Journal · doi:10.1053/euhj.1998.1099 · Cited by 191
Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses.
Ullian, M. E., Schelling, J. R., & Linas, S. L. (1992) · Hypertension · doi:10.1161/01.hyp.20.1.67 · Cited by 141
Endothelium as a Therapeutic Target in Heart Failure
Drexler, H. (1998) · Circulation · doi:10.1161/01.cir.98.24.2652 · Cited by 114
Kyrle, P. A., Eichler, H. G., Jäger, U., et al. (1987) · Circulation · doi:10.1161/01.cir.75.5.1025 · Cited by 90
Davidson, N. C., Barr, C. S., & Struthers, A. D. (1996) · Circulation · doi:10.1161/01.cir.93.6.1155 · Cited by 58
Self-citationWhy does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
Struthers, A. D. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00954.x · Cited by 41
Self-citation
Cited by
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4061 · Cited by 2,925
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554
Brutsaert, D. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00017.2002 · Cited by 697
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Self-citation
Metadata
- Authors
- Farquharson, C. A. J., & Struthers, A. D.
- Venue
- Circulation
- Published
- 2000-02-15
- Volume
- 101
- Issue
- 6
- Pages
- 594-597
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1969889097
- Cited by
- 532
- References
- 9
- FWCI
- 23.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure. https://app.cochat.ai/papers/10.1161/01.cir.101.6.594
- The paper
- Farquharson, C. A. J., & Struthers, A. D. (2000). Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure. Circulation. https://doi.org/10.1161/01.cir.101.6.594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.